01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Helpful resources for VAXNEUVANCE

From a health care professional

The burden of disease and the risk of IPD in the pediatric population1-3

Family nurse practitioner Wendy L. Wright discusses the burden and risk of IPD in pediatric patients1-3

Immunogenicity matters when selecting a PCV for your pediatric population1,4-7

Family nurse practitioner Wendy L. Wright looks at why immunogenicity matters when choosing a PCV for pediatric patients1,4-7

For your practice

Help protect against invasive pneumococcal disease in children

Learn about the ongoing risk of pediatric IPD and how VAXNEUVANCE can help protect
against it.1, 8-12

Image of Health Care Provider Resource on Disparities in IPD Vaccination Coverage

Disparities in IPD vaccination coverage

Important data on incomplete vaccine series among infants

View resource

EHR guidance

Useful instructions on adding VAXNEUVANCE to your EHR system

View resource
Image of Health Care Provider Resource on Ordering and Storing of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)

Getting started with VAXNEUVANCE

How to dose and administer, store and handle, and order VAXNEUVANCE

View resource
Image of Health Care Provider Resource on Protecting Pediatric Patients Against IPD in Their First Year of Life and Beyond

First year of life journey

Key details on protecting pediatric patients against IPD during this critical period

View resource

For your patients

Image of Patient Resource About Pediatric IPD and VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) in English

Help protect your baby from IPD with VAXNEUVANCE

A patient-friendly overview of pediatric IPD and VAXNEUVANCE

View resource
Image of Patient Resource About Pediatric IPD and VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) in Spanish

Help protect your baby from IPD with VAXNEUVANCE (Spanish)

A patient-friendly overview of pediatric IPD and VAXNEUVANCE in Spanish

View resource

EHR, electronic health record; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.

References

  1. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed May 1, 2024. Accessed August 1, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
  2. Centers for Disease Control and Prevention (CDC). Visualization – Based on 1998-2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance (ABCs). Updated July 22, 2024. Accessed September 27, 2024. https://data.cdc.gov/d/qvzb-qs6p/visualization
  3. Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance (ABCs) report, emerging infections program network, Streptococcus pneumoniae, 2021. https://www.cdc.gov/abcs/downloads SPN_Surveillance_ Report_2021.pdf
  4. Weekly epidemiological record. World Health Organization. 2019;85–104. Accessed January 26, 2024. https://www.who.int/publications/i/item/10665-310968
  5. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. World Health Organization. October 19, 2013. Accessed January 26, 2024. https://www.who.int/publications/m/item/pneumococcal-conjugate-vaccines-annex3-trs-977
  6. Gruber MF, Marshall VB. Chapter 80: Regulation and testing of vaccines in the US. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA, eds. Plotkin’s Vaccines. 8th ed. Elsevier; 2022;1640-1659.e2.
  7. Guidelines on clinical evaluation of vaccines, regulatory expectations. WHO Technical Report Series 1004, Annex 9, 2017. World Health Organization. Accessed May 28, 2024. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9
  8. Wasserman M, Chapman R, Lapidot R, et al. Twenty-year public health impact of 7- and 13-valent pneumococcal conjugate vaccines in US children. Emerging Infect Dis. 2021;27(6):1627- 1636.
  9. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package US-PVC-01698.
  10. Kaplan SL, Barson WJ, Lin Ling P, et al. Invasive Pneumococcal Disease in Children’s Hospitals: 2014- 2017. Pediatrics. 2019;144(3):e20190567.
  11. Centers for Disease Control and Prevention (CDC). About Pneumococcal Disease. Last reviewed February 6, 2024. Accessed July 9, 2024. https://www.cdc.gov/pneumococcal/about/?CDC_AAref_Val=https://www.cdc.gov/pneumococcal/about/infection-types.html
  12. Centers for Disease Control and Prevention (CDC). Pneumococcal Disease Symptoms and Complications. Last reviewed February 6, 2024. Accessed May 31, 2024. https://www.cdc.gov/pneumococcal/signs-symptoms/
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.